Pfizer Rethinks German Investments Amidst Drug Price Policy Concerns

Pfizer is reconsidering its investment plans in Germany due to proposed government policies aimed at lowering drug prices, CEO Albert Bourla informed Chancellor Friedrich Merz. The changes raise uncertainty in the pharmaceutical sector, prompting Pfizer and others to reassess their investment strategies.

Pfizer is reevaluating its investment strategy in Germany, as stated in a letter by CEO Albert Bourla to Chancellor Friedrich Merz. Citing proposed governmental policies that could reduce drug prices, Bourla expressed concerns over the potential unpredictability these changes bring to the pharmaceutical industry, particularly in terms of long-term investment decisions.

This revelation was presented in a letter dated June 9, shared with Reuters and first reported by Handelsblatt. Bourla mentioned that Pfizer is now reassessing its external engagements, along with the timing, scope, and prioritization of its planned investments in Germany.

This development follows similar moves by Eli Lilly, which decided to cut its $2.3 billion investment in half, and German firm Boehringer Ingelheim, which canceled its €900 million investment plans, both due to the country's proposed healthcare cost-cutting measures.